bluebird bio (NASDAQ:BLUE) Trading Up 12.6%
bluebird bio (NASDAQ:BLUE) Trading Up 12.6%
bluebird bio, Inc. (NASDAQ:BLUE – Get Rating)'s share price was up 12.6% during mid-day trading on Thursday . The company traded as high as $6.76 and last traded at $6.68. Approximately 174,236 shares traded hands during mid-day trading, a decline of 97% from the average daily volume of 5,735,633 shares. The stock had previously closed at $5.93.
藍鳥生物週四午盤股價上漲12.6%，最高報6.76美元，尾盤報6.68美元。午盤約有174,236股易手，較5,735,633股的日均成交量下跌97%。該股此前收盤報5.93美元。
Analyst Ratings Changes
分析師評級發生變化
A number of equities research analysts have recently issued reports on BLUE shares. Morgan Stanley reduced their price target on shares of bluebird bio to $3.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 17th. Barclays raised shares of bluebird bio from an "underweight" rating to an "equal weight" rating and boosted their price target for the company from $3.00 to $5.00 in a research note on Friday, August 5th. Raymond James upgraded shares of bluebird bio from a "market perform" rating to an "outperform" rating and set a $8.00 price objective for the company in a report on Tuesday, August 2nd. Finally, Wedbush dropped their price objective on shares of bluebird bio from $10.00 to $8.00 and set a "neutral" rating for the company in a report on Tuesday, May 10th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $10.50.
一些股票研究分析師最近發佈了關於藍股的報告。5月17日，週二，摩根士丹利在一份研究報告中將藍鳥生物的目標價下調至3.00美元，並對該股設定了“減持”評級。8月5日，巴克萊在一份研究報告中將藍鳥生物的股票評級從減持上調至同等權重，並將該公司的目標價從3.00美元上調至5.00美元。雷蒙德·詹姆斯在8月2日(週二)的一份報告中將藍鳥生物的股票評級從“市場表現”上調至“跑贏大盤”，併為該公司設定了8.00美元的目標價。最後，韋德布什在5月10日週二的一份報告中將藍鳥生物公司的股票目標價從10.00美元下調至8.00美元，並將該公司的評級定為中性。兩位投資分析師對該股的評級為賣出，九位給予持有評級，兩位給予買入評級，一位給予該公司強烈的買入評級。根據MarketBeat.com的數據，該公司目前的平均評級為持有，共識目標價為10.50美元。
bluebird bio Trading Up 8.4 %
藍鳥生物交易上漲8.4%
The company has a market cap of $495.88 million, a price-to-earnings ratio of -0.79 and a beta of 1.29. The firm's fifty day simple moving average is $4.39 and its 200 day simple moving average is $4.77.
該公司市值為4.9588億美元，市盈率為-0.79倍，貝塔係數為1.29。該公司的50日簡單移動均線為4.39美元，200日簡單移動均線為4.77美元。
Insider Activity
內幕活動
In other news, CEO Andrew Obenshain sold 21,805 shares of the company's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $4.39, for a total value of $95,723.95. Following the completion of the transaction, the chief executive officer now owns 247,131 shares in the company, valued at approximately $1,084,905.09. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, CEO Andrew Obenshain sold 21,805 shares of the company's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $4.39, for a total value of $95,723.95. Following the completion of the transaction, the chief executive officer now owns 247,131 shares in the company, valued at approximately $1,084,905.09. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Jason Cole sold 7,448 shares of the company's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $4.39, for a total transaction of $32,696.72. Following the completion of the transaction, the insider now owns 203,740 shares of the company's stock, valued at approximately $894,418.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,364 shares of company stock worth $146,664. Corporate insiders own 2.90% of the company's stock.
其他消息方面，首席執行官安德魯·奧本辛在8月4日(星期四)的一次交易中出售了21,805股公司股票。這些股票的平均價格為4.39美元，總價值為95,723.95美元。交易完成後，首席執行官現在擁有該公司247,131股，價值約1,084,905.09美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，可以通過以下鏈接獲得。其他消息方面，首席執行官安德魯·奧本辛在8月4日(星期四)的一次交易中出售了21,805股公司股票。這些股票的平均價格為4.39美元，總價值為95,723.95美元。交易完成後，首席執行官現在擁有該公司247,131股，價值約1,084,905.09美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，可以通過以下鏈接獲得。此外，內部人士傑森·科爾在8月4日星期四的一次交易中出售了7,448股該公司股票。這些股票以4.39美元的平均價格出售，總成交金額為32,696.72美元。交易完成後，這位內部人士現在擁有203,740股該公司股票，價值約894,418.60美元。此次拍賣的披露信息可在此處找到。上個季度，內部人士出售了34,364股公司股票，價值146,664美元。企業內部人士持有該公司2.90%的股份。
Institutional Trading of bluebird bio
藍鳥生物的制度性交易
Several institutional investors and hedge funds have recently bought and sold shares of BLUE. Duality Advisers LP raised its position in bluebird bio by 19.3% in the 4th quarter. Duality Advisers LP now owns 62,344 shares of the biotechnology company's stock valued at $623,000 after purchasing an additional 10,070 shares during the last quarter. Advisor Group Holdings Inc. raised its position in bluebird bio by 24.4% in the 4th quarter. Advisor Group Holdings Inc. now owns 18,058 shares of the biotechnology company's stock valued at $180,000 after purchasing an additional 3,543 shares during the last quarter. Toronto Dominion Bank purchased a new stake in bluebird bio in the 4th quarter valued at $1,426,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in bluebird bio by 145.1% in the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 26,363 shares of the biotechnology company's stock valued at $279,000 after purchasing an additional 15,609 shares during the last quarter. Finally, Northern Trust Corp raised its position in bluebird bio by 0.3% in the 4th quarter. Northern Trust Corp now owns 719,985 shares of the biotechnology company's stock valued at $7,193,000 after purchasing an additional 2,348 shares during the last quarter. Hedge funds and other institutional investors own 96.38% of the company's stock.
幾家機構投資者和對衝基金最近買賣了Blue的股票。Duality Advisers LP在第四季度將其在藍鳥生物的頭寸提高了19.3%。Duality Advisers LP現在擁有這家生物技術公司62,344股票，價值623,000美元，在上個季度又購買了10,070股票。Advisor Group Holdings Inc.在第四季度將其在藍鳥生物的持倉提高了24.4%。Advisor Group Holdings Inc.現在持有這家生物技術公司18,058股股票，價值18萬美元，上個季度又購買了3,543股。多倫多道明銀行在第四季度購買了藍鳥生物的新股份，價值1,426,000美元。三菱日聯國賽資產管理有限公司在第四季度將其在藍鳥生物的持倉提高了145.1%。三菱UFJ國賽資產管理有限公司在上個季度增持了15,609股後，現在持有26,363股這家生物技術公司的股票，價值27.9萬美元。最後，北方信託公司在第四季度將其在藍鳥生物的頭寸提高了0.3%。北方信託公司現在擁有719,985股生物技術公司的股票，價值7,193,000美元，在上個季度又購買了2,348股。對衝基金和其他機構投資者持有該公司96.38%的股票。
About bluebird bio
關於藍鳥傳記
(Get Rating)
(獲取評級)
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
藍鳥生物公司是一家生物技術公司，研究、開發和商業化針對嚴重遺傳病的變革性基因療法。其用於治療嚴重遺傳性疾病的候選產品包括用於治療輸血依賴型β-地中海貧血的貝替貝吉基因Autotemcel；用於治療鐮狀細胞病(SCD)的lovotieglogene autemcel；以及用於治療大腦腎上腺腦白質營養不良的伊利伐多烯Autotemcel。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
- Find and Profitably Trade Stocks at 52-Week Lows
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
- 3 Stable Growth Stocks for Bumpy Times
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
- 免費獲取StockNews.com關於藍鳥生物的研究報告(藍色)
- 找到並獲利於52周低點的股票交易
- 迪士尼(NYSE：DIS)的股票剛剛給了投資者一個巨大的信號
- 清潔能源法案通過後，太陽能股大放異彩
- 顛簸時代的3只穩定成長股
- 大型和小型石油和天然氣類股盈利後反彈
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.
獲得藍鳥生物日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對藍鳥生物和相關公司的最新新聞和分析師評級的每日簡明摘要。